Literature DB >> 23473474

New era of radiotherapy: an update in radiation-induced lung disease.

M F K Benveniste1, J Welsh, M C B Godoy, S L Betancourt, O R Mawlawi, R F Munden.   

Abstract

Over the last few decades, advances in radiotherapy (RT) technology have improved delivery of radiation therapy dramatically. Advances in treatment planning with the development of image-guided radiotherapy and in techniques such as proton therapy, allows the radiation therapist to direct high doses of radiation to the tumour. These advancements result in improved local regional control while reducing potentially damaging dosage to surrounding normal tissues. It is important for radiologists to be aware of the radiological findings from these advances in order to differentiate expected radiation-induced lung injury (RILD) from recurrence, infection, and other lung diseases. In order to understand these changes and correlate them with imaging, the radiologist should have access to the radiation therapy treatment plans.
Copyright © 2013 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23473474      PMCID: PMC3941603          DOI: 10.1016/j.crad.2013.01.013

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  54 in total

Review 1.  Optimizing dose and fractionation for stereotactic body radiation therapy. Normal tissue and tumor control effects with large dose per fraction.

Authors:  Robert Timmerman; Michael Bastasch; Debabrata Saha; Ramzi Abdulrahman; William Hittson; Michael Story
Journal:  Front Radiat Ther Oncol       Date:  2007

2.  Photons or protons: precision radiotherapy of lung cancer.

Authors:  Thomas Auberger; Karl Seydl; Tanja Futschek; Arpad Sztankay; Reinhart A Sweeney; Peter Lukas
Journal:  Strahlenther Onkol       Date:  2007-12       Impact factor: 3.621

3.  Contrast enhanced 4D-CT imaging for target volume definition in pancreatic ductal adenocarcinoma.

Authors:  Pietro Mancosu; Valentino Bettinardi; Paolo Passoni; Simone Gusmini; Stefano Cappio; Maria C Gilardi; Giovanni M Cattaneo; Michele Reni; Alessandro Del Maschio; Nadia Di Muzio; Ferruccio Fazio
Journal:  Radiother Oncol       Date:  2008-05-15       Impact factor: 6.280

4.  Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer.

Authors:  Joe Y Chang; Xiaodong Zhang; Xiaochun Wang; Yixiu Kang; Beverly Riley; Stephen Bilton; Radhe Mohan; Ritsuko Komaki; James D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-05-06       Impact factor: 7.038

5.  Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT).

Authors:  Shulian Wang; Zhongxing Liao; Xiong Wei; Helen H Liu; Susan L Tucker; Chao-Su Hu; Rodhe Mohan; James D Cox; Ritsuko Komaki
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-09-25       Impact factor: 7.038

6.  Phase II study on stereotactic body radiotherapy of colorectal metastases.

Authors:  Morten Hoyer; Henrik Roed; Anders Traberg Hansen; Lars Ohlhuis; Jorgen Petersen; Hanne Nellemann; Anne Kiil Berthelsen; Cai Grau; Svend Aage Engelholm; Hans Von der Maase
Journal:  Acta Oncol       Date:  2006       Impact factor: 4.089

7.  Comparison of outcomes for patients with medically inoperable Stage I non-small-cell lung cancer treated with two-dimensional vs. three-dimensional radiotherapy.

Authors:  L Christine Fang; Ritsuko Komaki; Pamela Allen; Thomas Guerrero; Radhe Mohan; James D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-09-01       Impact factor: 7.038

8.  Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study.

Authors:  Pia Baumann; Jan Nyman; Morten Hoyer; Giovanna Gagliardi; Ingmar Lax; Berit Wennberg; Ninni Drugge; Lars Ekberg; Signe Friesland; Karl-Axel Johansson; Jo-Smund Lund; Elisabeth Morhed; Kristina Nilsson; Nina Levin; Merete Paludan; Christer Sederholm; Anders Traberg; Lena Wittgren; Rolf Lewensohn
Journal:  Radiother Oncol       Date:  2008-09-01       Impact factor: 6.280

Review 9.  Advances in 4D medical imaging and 4D radiation therapy.

Authors:  G Li; D Citrin; K Camphausen; B Mueller; C Burman; B Mychalczak; R W Miller; Y Song
Journal:  Technol Cancer Res Treat       Date:  2008-02

10.  PET/CT and hepatic radiation injury in esophageal cancer patients.

Authors:  Revathy B Iyer; Aparna Balachandran; John F Bruzzi; Valen Johnson; Homer A Macapinlac; Reginald F Munden
Journal:  Cancer Imaging       Date:  2007-11-26       Impact factor: 3.909

View more
  24 in total

1.  Upstaging, not just a non-small matter.

Authors:  Daniel C Thomas; Anthony W Kim
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

2.  Isoflavone-mediated radioprotection involves regulation of early endothelial cell death and inflammatory signaling in Radiation-Induced lung injury.

Authors:  Matthew D Fountain; Laura A McLellan; Natalie L Smith; Brian F Loughery; Joseph T Rakowski; Harley Y Tse; Gilda G Hillman
Journal:  Int J Radiat Biol       Date:  2019-11-04       Impact factor: 2.694

3.  Adenovirus-mediated Foxp3 expression in lung epithelial cells ameliorates acute radiation-induced pneumonitis in mice.

Authors:  D Shin; G Lee; S Lee; S Park; K-H Jung; J H Lee; J M Lee; J-Y Kim; J Cho; H Bae
Journal:  Gene Ther       Date:  2016-12-20       Impact factor: 5.250

4.  Tenascin C in radiation-induced lung damage: Pathological expression and serum level elevation.

Authors:  Yutaka Toyomasu; Kenta Matsui; Kazuki Omori; Akinori Takada; Kyoko Imanaka-Yoshida; Isao Tawara; Akira Shimamoto; Motoshi Takao; Hiroyasu Kobayashi; Atsushi Tomaru; Hajime Fujimoto; Tetsu Kobayashi; Haiime Sakuma; Yoshihito Nomoto
Journal:  Thorac Cancer       Date:  2022-09-01       Impact factor: 3.223

5.  NRF2/miR-140 signaling confers radioprotection to human lung fibroblasts.

Authors:  Nadire Duru; Ramkishore Gernapudi; Yongshu Zhang; Yuan Yao; Pang-Kuo Lo; Benjamin Wolfson; Qun Zhou
Journal:  Cancer Lett       Date:  2015-08-20       Impact factor: 8.679

6.  Therapeutic effects of C-28 methyl ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO-Me; bardoxolone methyl) on radiation-induced lung inflammation and fibrosis in mice.

Authors:  Yan-Yang Wang; Cui-Ying Zhang; Ya-Qiong Ma; Zhi-Xu He; Hong Zhe; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2015-06-22       Impact factor: 4.162

7.  Clarithromycin Attenuates Radiation-Induced Lung Injury in Mice.

Authors:  Seung Jun Lee; Chin-ok Yi; Rok Won Heo; Dae Hyun Song; Yu Ji Cho; Yi Yeong Jeong; Ki Mun Kang; Gu Seob Roh; Jong Deog Lee
Journal:  PLoS One       Date:  2015-06-26       Impact factor: 3.240

8.  Opposite roles for p38MAPK-driven responses and reactive oxygen species in the persistence and resolution of radiation-induced genomic instability.

Authors:  Erica Werner; Huichen Wang; Paul W Doetsch
Journal:  PLoS One       Date:  2014-10-01       Impact factor: 3.240

9.  CT findings of acute radiation-induced pneumonitis in breast cancer.

Authors:  Wonguen Jung; Sung Shine Shim; Kyubo Kim
Journal:  Br J Radiol       Date:  2021-06-16       Impact factor: 3.629

10.  Expression of interleukin-17A in lung tissues of irradiated mice and the influence of dexamethasone.

Authors:  Li-Ping Wang; Yan-Wen Wang; Bao-Zhong Wang; Gui-Ming Sun; Xiu-Yu Wang; Jun-Long Xu
Journal:  ScientificWorldJournal       Date:  2014-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.